hrp0095p1-356 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Use of The Arginine-Stimulated Copeptin Test in Polyuric Syndrome in Paediatrics. Experience in Three Patients

Gonzalez-Llorens Nuria , Biagetti Biagetti Betina , Mogas Viñals Eduard , Puerto Carranza Elsa , Tomasini Rosangela , Campos Martorell Ariadna , Yeste Fernandez Diego , Clemente Leon Maria

Introduction: Differential diagnosis of partial central diabetes insipidus (PCDI) and primary polydipsia (PP) can be challenging. Copeptin is the C-terminal segment of the vasopressin precursor peptide that represents a novel and stable biomarker. Arginine infusion produces a nonosmotic stimulus that causes an increase in copeptin concentrations in healthy subjects. Arginine-stimulated copeptin concentrations have been used to differentiate between patients wi...

hrp0092fc14.1 | GH and IGF1 | ESPE2019

Inhibition of IGF1R by IGF1R/IR Inhibitor OSI906 as a Targeted Therapy for Glioblastoma: in vitro & in vivo Studies

Fernandez Maria Celia , Martin Ayelen , Clément Florencia , Venara Marcela , Fernanda Castro Julia , Lombardi Mercedes Garcia , Bergadá Ignacio , Pennisi Patricia

Background: CNS tumours are the most frequent solid tumours in children. In pediatric gliomas, IGF1R nuclear localization was significantly associated with both high grade tumours and increased risk of death and contributed to the aggressive phenotype of glioblastoma by increasing motility and metabolism of tumour cells rather than increasing its proliferation. For children chemotherapy after surgical resection is the mainstay of therapy. However, the best reg...

hrp0092p3-320 | Late Breaking Abstracts | ESPE2019

EpiPEG-PreMeb Study: Chemerina Plasmatic and Metabolic Syndrome Relation at SGA Childrens

Diez-Lopez Ignacio , Sarasua-Miranda Ainhoa , Leniz Asier , Fernandez-Quintela Alfredo , Portillo Maria Puy , Macarulla-Arenaza Maria Teresa , Lorente-Blazquez Isabel

The objective of this study has been the analysis of plasma chemistry in a group of children born SGA at the University Hospital of Álava- Txagorritxu and biochemical parameters related to the metabolic syndrome.Material and Methods: In a cohort of 27 subjects sub (13 boys and 14 girls) from the epiPEG-PreMeb study, a blood sample at 3, 12 and 24 months of life it was extracted. Biochemical parameters s and measured by automated and...

hrp0089p3-p204 | GH & IGFs P3 | ESPE2018

Children Born Small for Gestational Age Treated with Growth Hormone: Evolutionary Aspects

Vazquez Veronica Maria Padin , Costa David Albino Gomez , Garcia Aida Del Campo , Cordo Lourdes Rey , Martin Jose Luis Chamorro , Lorenzo Jose Ramon Fernandez

Introduction: Short stature is defined as stature less than −2 standars deviations (SD) for a person’s age and sex of the reference population. Short for gestational age children (SGA) represent 20% of all children with short stature. 10% of these can not catch-up and remains their height below −2 SD. Growth hormone (GH) treatment is a recognized therapy for SGA children authorized in Europe at 4 years old. There are studies that support that younger children ...

hrp0089p3-p211 | GH & IGFs P3 | ESPE2018

Study of the Effectiveness of GH in Children Born Small for Gestational Age in an Area of Northwestern Spain and its Associated Factors

Rodriguez Paloma Cabanas , Cordo Lourdes Rey , Fernandez Antonio Bello , Martin Jose Luis Chamorro , Carro Ana Prado , Rego Ruben , Castro-Feijoo Lidia , Dans Alicia Cepedano , Conde Jesus Barreiro

Introduction: Recombinant GH is an effective treatment for short children who are born small for gestational age(SGA). Short children SGA who fail catch-up growth by 4 years of age are candidates for GH treatment, at a dose of 35–70 μg/kg per day. Factors associated with response to GH treatment during the initial 2–3 years of therapy include age and height standard deviation scores at the start of therapy, midparental height, and GH dose. It is important to kno...

hrp0089p3-p240 | Growth & Syndromes P3 | ESPE2018

The Expression of Cytokines in SGA Children Throughout Lactation Allows to Characterize Early the Type of Cath-up

Diez-Lopez Ignacio , Sarasua Ainhoa , delHoyo Marta , Lorente Isabel , Segura Raquel Gomez de , Picon Minerva , Leniz Asier , Fernandez Alfredo , Puy-Portillo Maria

Up to 50% of children born SGA at 2 years have not made a correct catch up (by excess or defect), with repercussions on size, metabolic and cardiovascular alterations, DM, etc. The Project has developed a prospective cohort of SGA and seeks to study phenotypic, BQ and genetic differences that explain their different behavior.Material and methods: We study live births of single pregnancies in our Hospital during 2012–2014, and are classified accordin...

hrp0089p3-p331 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology P3 | ESPE2018

GnRH Analogues and Cross-Sex Hormonal therapy: Side Effects in Transgender Youth

Palma Cristina Mora , Fernandez Julio Guerrero , Martin Nerea Itza , Villalobos Arancha Ortiz , Bonis Ana Coral Barreda , Fresno Luis Salamanca , Casado Isabel Gonzalez

Background: Transsexuality during childhood/adolescence is a complex condition usually ending in dysphoria (GD). The prevalence of transgenderism is increasing in Pediatrics. In the process of sexual reassignment, a correct pharmacological treatment and the knowledge of possible consequences are necessary.Objetive: The objective of this study is to present the evolution of the physical and analytical characteristics and side effects in Transgender childr...

hrp0086rfc10.2 | Perinatal Endocrinology | ESPE2016

Dysregulation of Placental Mirna in Maternal Obesity is Associated with Pre-and Post-Natal Growth

Bassols Judit , Carreras-Badosa Gemma , Bonmati Alexandra , Ortega Francisco-Jose , Mercader Josep-Maria , Prats-Puig Anna , deZegher Francis , Ibanez Lourdes , Fernandez-Real Jose-Manuel , Lopez-Bermejo Abel

Background: Human placenta exhibits a specific miRNA expression pattern. Some of these miRNAs are dysregulated in pregnancy disorders like preeclampsia and intrauterine growth restriction (IUGR), and are potential biomarkers for these pathologies. No studies have been performed in maternal obesity.Objective and hypotheses: (1) Define the placental miRNA profile in pregnant women with: a) pre-pregnancy (preOB) or gestational obesity (gestOB), b) gestation...

hrp0086rfc10.8 | Perinatal Endocrinology | ESPE2016

Gestational Diabetes is Associated with Changes in Placental Microbiota and Microbiome

Bassols Judit , Serino Matteo , Carreras-Badosa Gemma , Burcelin Remy , Blasco-Baque Vincent , Prats-Puig Anna , de Zegher Francis , Ibanez Lourdes , Fernandez-Real Jose-Manuel , Lopez-Bermejo Abel

Background: The human microbiota has emerged as an unexpected modulator of the immune system. The placenta, long thought to be sterile, harbors a unique microbiome and variations in their composition could be related to prevent pregnancy disorders.Objective and hypotheses: To profile the placental microbiota (microorganisms) and microbiome (collection of microbial genomes in an environment) in women with gestational diabetes (GDM) and study their relatio...

hrp0086rfc13.7 | Management of Obesity | ESPE2016

Early Onset Obesity and Hyperphagia Associated with Defects in the GNAS Gene

Garcia Marta , Espinosa Nuria , Guerrero-Fernandez Julio , Salamanca Luis , Morais Ana , Gracia Ricardo , Elkoro Intza Garin , Casado Isabel Gonzalez , de Nanclares Guiomar Perez , Moreno Jose C.

Background: Imprinted genes are known to regulate fetal growth and a ‘parental conflict’ model predicts that paternally and maternally expressed imprinted genes promote and inhibit fetal growth, respectively. GNAS is a complex imprinted locus with multiple oppositely imprinted gene products. Maternal, but not paternal, G(s)alpha mutations lead to obesity in pseudohypoparathyroidism type IA (PHPIA). However, the disorder rarely causes severe obesity in infancy as pred...